| Literature DB >> 25895921 |
.
Abstract
In the first randomized trial to compare FDA-approved immune checkpoint inhibitors as first-line therapy for patients with advanced melanoma, pembrolizumab yielded significantly better treatment outcomes than ipilimumab. ©2015 American Association for Cancer Research.Entities:
Mesh：
Substances：
Year: 2015 PMID： 25895921 DOI： 10.1158/2159-8290.CD-NB2015-055
Source DB: PubMed Journal: Cancer Discov ISSN： 2159-8274 Impact factor: 39.397